Hormone-refractory (D3) prostate cancer: refining the concept. (Q40453963)

20 September 2017

1 reference

title

Hormone-refractory (D3) prostate cancer: refining the concept. (English)

1 reference

20 September 2017

2

1 reference

20 September 2017

Scher HI

1

1 reference

PubMed ID

7624983

20 September 2017

Kelly WK

series ordinal

3

1 reference

PubMed ID

7624983

20 September 2017

language of work or name

English

0 references

publication date

1 August 1995

1 reference

20 September 2017

1 reference

20 September 2017

46

1 reference

20 September 2017

2

1 reference

20 September 2017

142-148

1 reference

Hormone therapy in prostatic cancer

20 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980182-4

7 January 2021

Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980182-4

7 January 2021

A controlled trial of leuprolide with and without flutamide in prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980182-4

7 January 2021

Phase II evaluation of coumarin (1,2-benzopyrone) in metastatic prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980182-4

7 January 2021

Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980182-4

7 January 2021

Response to flutamide withdrawal in advanced prostate cancer in progression under combination therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980182-4

7 January 2021

Surprising activity of flutamide withdrawal, when combined with aminoglutethimide, in treatment of "hormone-refractory" prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980182-4

7 January 2021

Use of palliative end points to evaluate the effects of mitoxantrone and low-dose prednisone in patients with hormonally resistant prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980182-4

7 January 2021

Suramin and prostate cancer: The role of hydrocortisone

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980182-4

7 January 2021

Suramin, an active drug for prostate cancer: interim observations in a phase I trial

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980182-4

7 January 2021

Prostate-specific antigen decline after casodex withdrawal: evidence for an antiandrogen withdrawal syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980182-4

7 January 2021

Benefits of combination therapy with flutamide in patients relapsing after castration

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980182-4

7 January 2021

Neuroendocrine differentiation in human prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980182-4

7 January 2021

Orchiectomy versus goserelin and flutamide in the treatment of newly diagnosed metastatic prostate cancer. Analysis of the criteria of evaluation used in the European Organization for Research and Treatment of Cancer--Genitourinary Group Study 30853

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980182-4

7 January 2021

Cortical steroids in treatment of cancer; observations on effects of pituitary adrenocorticotropic hormone (ACTH) and cortisone in far advanced cases.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980182-4

7 January 2021

Response to aminoglutethimide and cortisone acetate in advanced prostatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980182-4

7 January 2021

Cortisone treatment in advanced carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980182-4

7 January 2021

Androgen suppression by hydrocortisone without aminoglutethimide in orchiectomised men with prostatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980182-4

7 January 2021

Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980182-4

7 January 2021

A phase II randomized trial of megestrol acetate or dexamethasone in the treatment of hormonally refractory advanced carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980182-4

7 January 2021

Treatment of stage D2 prostatic cancer refractory to or relapsed following castration plus oestrogens. Comparison of aminoglutethimide plus hydrocortisone with medroxyprogesterone acetate plus hydrocortisone

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980182-4

7 January 2021

Clinical and biochemical effect of aminoglutethimide in the treatment of advanced prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980182-4

7 January 2021

A study of aminoglutethemide and hydrocortisone in patients with advanced and refractory prostate carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980182-4

7 January 2021

Clinical effect of aminoglutethimide, medical adrenalectomy, in treatment of 43 patients with advanced prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980182-4

7 January 2021

Anti-hormone treatment for prostate cancer relapsing after treatment with flutamide and castration. Addition of aminoglutethimide and low dose hydrocortisone to combination therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980182-4

7 January 2021

Medical adrenalectomy for advanced prostatic cancer: clinical and hormonal effects.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980182-4

7 January 2021

Treatment of advanced prostatic cancer, resistant to conventional therapy, with aminoglutethimide

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980182-4

7 January 2021

Suramin: a novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980182-4

7 January 2021

Suramin for prostatic cancer: a phase I/II study in advanced extensively pretreated disease

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980182-4

7 January 2021

10.1016/S0090-4295(99)80182-4

Identifiers

DOI

1 reference

20 September 2017

1 reference

PubMed ID

7624983